Sites sur "Les Conquérants du feu"

Evaluation of ocrelizumab in older progressive multiple sclerosis patients : Seminal trials evaluating anti-CD20 therapy in progressive MS primarily found benefit in younger, less-disabled patients with more inflammatory diseas?
Older Patients With MS Face Additional Risks With Ocrelizumab Treatment : Luxenberg and colleagues conducted a retrospective analysis of all ocrelizumab-treated patients infused at the University of Washington MS Center?s infusion suite in order to assess clinical and laboratory parameters in patients over the age of 55 years.
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage ... : This subgroup analysis assessed the long-term e fficacy and safety pro file of the high-e fficacy DMT ocrelizumab (OCR) as rst-line therapy for early-stage relapsing MS (RMS).
AAN 2026: Ocrevus treatment slows disability in advanced PPMS : Trial data showed Ocrevus treatment slowed disability progression in PPMS, including patients who were older and had more advanced disease.
Evaluation of ocrelizumab in older progressive multiple sclerosis patients : Methods: Retrospective chart review was performed for patients older than 55 with primary or secondary progressive MS at the time of ocrelizumab initiation. Clinical endpoints from 2 years prior to anti-CD20 therapy served as a within-subject control.
New data further reinforce Roche?s OCREVUS (ocrelizumab) as a highly ... : A 97% treatment persistence for OCREVUS patients at 18 months, and strong adherence to infusions every six months, was seen in an interim analysis of more than 1,600 patients in the ongoing German CONFIDENCE study.
Long-Term Data of Ocrelizumab Highlights Specific Patient Population at ... : New 6-year data from the ACAPELLA study, a real-world analysis of patients with multiple sclerosis (MS) on ocrelizumab (Ocrevus; Genentech), showed a higher rate of severe infection in treated patients aged 55 years and older with an Expanded Disability Status Scale (EDSS) score of 6 points or more.
Results - Clinical Review Report: Ocrelizumab (Ocrevus) - NCBI Bookshelf : Grade 4 reaction: The infusion was stopped immediately and the patient received appropriate treatment; these patients were withdrawn from study treatment and a safety follow-up period was initiated.
Effectiveness of Ocrelizumab in Primary Progressive Multiple ... - Springer : Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis (PPMS) has been evaluated during phase 3 trials that enrolled patients ...
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis ... : Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-expressing B cells. The effect of ocrelizumab on primary progres?